Display options
Cite
Morowvat MH, Babaeipour V, Rajabi Memari H, et al. Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology. Jundishapur J Microbiol. 2015;8(4):e16236doi: 10.5812/jjm.8(4)2015.16236.
Morowvat, M. H., Babaeipour, V., Rajabi Memari, H., & Vahidi, H. (2015). Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology. Jundishapur journal of microbiology, 8(4), e16236. https://doi.org/10.5812/jjm.8(4)2015.16236
Morowvat, Mohammad Hossein, et al. "Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology." Jundishapur journal of microbiology vol. 8,4 (2015): e16236. doi: https://doi.org/10.5812/jjm.8(4)2015.16236
Morowvat MH, Babaeipour V, Rajabi Memari H, Vahidi H. Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology. Jundishapur J Microbiol. 2015 Apr 18;8(4):e16236. doi: 10.5812/jjm.8(4)2015.16236. eCollection 2015 Apr. PMID: 26034535; PMCID: PMC4449858.
Copy Download .nbib Format: NLM
Share it on

Jundishapur J Microbiol. 2015 Apr 18;8(4):e16236. doi: 10.5812/jjm.8(4)2015.16236. eCollection 2015 Apr.

Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology.

Jundishapur journal of microbiology

Mohammad Hossein Morowvat, Valiollah Babaeipour, Hamid Rajabi Memari, Hossein Vahidi

Affiliations

  1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran ; Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  2. Biochemical Engineering Group, Biotechnology Research Center, Malek-Ashtar University of Technology, Tehran, IR Iran ; Department of Bioscience Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, IR Iran.
  3. Department of Agronomy and Plant Breeding, College of Agriculture, Shahid Chamran University of Ahvaz, Ahvaz, IR Iran.
  4. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

PMID: 26034535 PMCID: PMC4449858 DOI: 10.5812/jjm.8(4)2015.16236

Abstract

BACKGROUND: The periplasmic overexpression of recombinant human interferon beta (rhIFN-β)-1b using a synthetic gene in Escherichia coli BL21 (DE3) was optimized in shake flasks using Response Surface Methodology (RSM) based on the Box-Behnken Design (BBD).

OBJECTIVES: This study aimed to predict and develop the optimal fermentation conditions for periplasmic expression of rhIFN-β-1b in shake flasks whilst keeping the acetate excretion as the lowest amount and exploit the best results condition for rhIFN-β in a bench top bioreactor.

MATERIALS AND METHODS: The process variables studied were the concentration of glucose as carbon source, cell density prior the induction (OD 600 nm) and induction temperature. Ultimately, a three-factor three-level BBD was employed during the optimization process. The rhIFN-β production and the acetate excretion served as the evaluated responses.

RESULTS: The proposed optimum fermentation condition consisted of 7.81 g L(-1) glucose, OD 600 nm prior induction 1.66 and induction temperature of 30.27°C. The model prediction of 0.267 g L(-1) of rhIFN-β and 0.961 g L(-1) of acetate at the optimum conditions was verified experimentally as 0.255 g L(-1) and 0.981 g L(-1) of acetate. This agreement between the predicted and observed values confirmed the precision of the applied method to predict the optimum conditions.

CONCLUSIONS: It can be concluded that the RSM is an effective method for the optimization of recombinant protein expression using synthetic genes in E. coli.

Keywords: Acetic acid; Escherichia coli; Interferon-beta; Periplasmic

References

  1. Pharmacol Ther. 2012 Jul;135(1):44-53 - PubMed
  2. Microbiol Mol Biol Rev. 2005 Mar;69(1):12-50 - PubMed
  3. Expert Rev Vaccines. 2008 Apr;7(3):373-81 - PubMed
  4. Trends Biotechnol. 2006 Nov;24(11):530-6 - PubMed
  5. Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):14-28 - PubMed
  6. J Biomed Biotechnol. 2011;2011:174615 - PubMed
  7. Iran J Pharm Res. 2014 Winter;13(Suppl):151-60 - PubMed
  8. J Microbiol Biotechnol. 2007 Aug;17(8):1236-41 - PubMed
  9. Int J Clin Pract. 2010 Apr;64(5):637-50 - PubMed
  10. Curr Opin Biotechnol. 2001 Apr;12(2):195-201 - PubMed
  11. Biotechnol Bioeng. 2001 Nov 20;75(4):439-50 - PubMed
  12. Gut Liver. 2009 Mar;3(1):20-5 - PubMed
  13. Arthritis Rheum. 2000 Feb;43(2):270-4 - PubMed
  14. Anal Chim Acta. 2007 Aug 6;597(2):179-86 - PubMed
  15. J Chromatogr A. 2007 Jul 27;1158(1-2):2-14 - PubMed
  16. Biotechnol Bioeng. 2009 Feb 1;102(2):468-82 - PubMed
  17. Expert Opin Biol Ther. 2010 Oct;10(10):1489-500 - PubMed
  18. Biomol Eng. 2007 Jun;24(2):217-22 - PubMed
  19. J Ind Microbiol. 1996 Mar;16(3):145-54 - PubMed
  20. Talanta. 2008 Sep 15;76(5):965-77 - PubMed
  21. Microb Cell Fact. 2008 Apr 04;7:11 - PubMed
  22. Appl Microbiol Biotechnol. 2006 Sep;72(2):211-22 - PubMed
  23. BMC Syst Biol. 2010 Dec 01;4:166 - PubMed
  24. Arthritis Res. 2002;4(6):346-52 - PubMed

Publication Types